Skip to main content

Table 2 Characteristics of the participants

From: Home-based cardio-oncology rehabilitation using a telerehabilitation platform in hematological cancer survivors: a feasibility study

Variable

Home-based CORE (n = 11)

Age [M (SD)]

60.3 (10.2)

< 60 years (n)

2 (18%)

≥ 60 years (n)

9 (82%)

Sex

 

Female (n)

8 (73%)

Male (n)

3 (27%)

Body mass index [M (SD)]

28.3 (3.0)

Average weight (n)

3 (27%)

Overweight and Obese (n)

8 (73%)

Marital status

 

Not married (n)

3 (27%)

Married (n)

8 (73%)

Children living at home

 

None (n)

8 (73%)

One or more (n)

3 (27%)

Education

 

University not completed (n)

6 (55%)

Completed university (n)

5 (45%)

Employment status

 

Not retired (n)

6 (55%)

Retired (n)

5 (45%)

Cancer type

 

Folicular lymphoma (n)

8 (73%)

Diffuse large B-cell lymphoma (n)

3 (27%)

Years since diagnosis [M (SD)]

1.6 (1.3)

≤ 3 years (n)

9 (82%)

> 3 years (n)

2 (18%)

Current cancer status

 

Disease free (n)

8 (73%)

Existing disease (n)

3 (27%)

Treatment status

 

Receiving maintenance treatment (n)

8 (73%)

Completed treatments (n)

3 (27%)

Stage at diagnosis

 

Stage II (n)

4 (36%)

Stage III (n)

4 (36%)

Stage IV (n)

3 (28%)

Cardiovascular characteristics

 

Diabetes mellitus (n)

3 (28%)

Hypertension (n)

5 (45%)

Dyslipidemia, (n)

4 (36%)

  1. maintenance treatment - rituximab 1.400 mg, subcutaneous injections (every 3 months, up to 2 years);